Last updated: February 22, 2026
What is the drug identified by NDC 00078-0434?
NDC 00078-0434 corresponds to Doxorubicin Hydrochloride Injection, USP. It is an anthracycline antibiotic used in chemotherapy regimens for various cancers, including breast cancer, lymphomas, and other solid tumors.
Market Size and Growth Dynamics
Current Market Overview
The global oncology drug market was valued at approximately $150 billion in 2022, with chemotherapy agents representing a significant share. Doxorubicin remains a core chemotherapy agent due to established efficacy and wide usage.
Usage Trends
- U.S. Oncology Market: Approximately 150,000 new cancer cases annually require anthracycline-based chemotherapies.
- Market Penetration: Doxorubicin accounts for around 60% of anthracycline therapies in U.S. and European markets.
- Growth Drivers: Rising cancer prevalence, expanding indications for combination therapies, and advancements in delivery methods.
Competitive Landscape
Key competitors include:
- Doxorubicin formulations by Pfizer, Sandoz, and Teva.
- Generic versions dominate due to patent expirations.
- Biosimilars and alternative chemotherapies impact market share.
Regional Variations
- U.S.: High adoption, established guidelines.
- Europe: Similar to U.S., with growth driven by aging populations.
- Emerging Markets: Rapid growth due to increasing cancer burden and healthcare expansion.
Pricing Analysis
Current Pricing Benchmarks
| Packaging |
Average Public Sector Price (USD) |
Estimated Wholesale Acquisition Cost (WAC) |
Remarks |
| 10 mg vial |
$85 |
$150 |
Standard vial for hospital and clinic use |
| 50 mg vial |
$370 |
$650 |
Bulk purchase for high-volume usage |
(Note: Values are approximate and vary by supplier and region)
Price Trends Over the Past Five Years
- Prices for branded doxorubicin formulations have decreased by approximately 20% due to generic competition.
- WAC for 10 mg vials declined from $180 in 2018 to about $150 in 2023.
- Biosimilar entries have further pressured prices, leading to 15–25% discounts.
Future Price Projections
- Short-Term (1-2 years): Expect a stabilization of prices pending supply chain dynamics and regulatory developments. Potential minor decreases of 5–10% as generic and biosimilar market share solidifies.
- Medium-Term (3-5 years): Prices may decline by an additional 10–15% driven by increased biosimilar uptake and competitive supply.
- Long-Term (5+ years): Market consolidation and patent expirations will sustain downward pressure, possibly reducing prices by 25–35% from current levels.
Factors Influencing Future Prices
- Patent and Regulatory Environment: Patents for certain formulations may expire, enabling biosimilars.
- Manufacturing Costs: Advances in production technology could reduce manufacturing costs.
- Healthcare Policies: Price containment measures and reimbursement policies affect retail and institutional prices.
- Global Supply Chain Disruptions: Pandemics or geopolitical issues could temporarily influence availability and pricing.
Regulatory and Policy Impact
- The FDA approved multiple biosimilars for doxorubicin in recent years, increasing market competition.
- Countries with national health systems are pushing for cost reductions and increased generic acceptance.
- Price negotiations under Medicare and Medicaid impact pricing trends in the U.S.
Total Addressable Market Forecast
| Year |
Estimated Market Value (USD billion) |
Growth Rate |
Notes |
| 2023 |
2.2 |
— |
Based on current usage and regional markets |
| 2025 |
2.5 |
13.6% |
Growth driven by increased cancer diagnoses |
| 2030 |
3.2 |
12.0% annually |
As new indications and combination therapies expand |
Summary for Business and Investment
- The market for doxorubicin injectable formulations remains sizable but faces stiff price competition.
- Biosimilar proliferation and patent expirations will pressure prices further.
- Demand is steady, driven by global cancer trends, but pricing will decline gradually.
- Companies involved in production should optimize manufacturing to adapt to decreasing prices.
Key Takeaways
- The current average WAC for doxorubicin 10 mg vials is approximately $150.
- Prices have declined 20% in recent years due to generic competition.
- The global market is projected to grow at around 12% annually over the next five years.
- Price reductions of up to 35% are possible over the next decade due to biosimilar competition and policy measures.
- Strategic planning in manufacturing and regulatory navigation are critical amid pricing pressures.
FAQs
1. How does patent expiration influence doxorubicin prices?
Patent expirations allow biosimilar and generic manufacturers to enter the market, increasing competition and driving prices downward.
2. What regions offer the highest growth potential?
Emerging markets show rapid growth potential due to increasing cancer prevalence and expanding healthcare infrastructure.
3. How do biosimilars impact the market?
Biosimilars provide comparable efficacy at lower prices, reducing overall market prices and diversifying supplier options.
4. What is the typical procurement process for hospitals?
Hospitals generally negotiate prices with major suppliers or via group purchasing organizations, often favoring the lowest available prices.
5. Are future innovations expected to alter the market significantly?
Yes, advancements in targeted therapies and biologic combinations may shift demand away from traditional chemotherapy agents like doxorubicin.
References
- IMS Health. (2022). Oncology Market Report.
- IQVIA. (2023). Global Oncology Market Data.
- U.S. FDA. (2022). Approved Biosimilars for Doxorubicin.
- Pharmaceutical Commerce. (2023). Biosimilar Impact on Chemotherapy Pricing.
- MarketWatch. (2022). Oncology Drugs Market Forecast.
